{"links":"<p><a href=\"https://cdn-auth-cms.who.int/media/docs/default-source/malaria/world-malaria-reports/world-malaria-report-2021-global-briefing-kit-eng.pdf\">Briefing kit for Global Messaging</a></p><p><a href=\"https://cdn-auth-cms.who.int/media/docs/default-source/malaria/world-malaria-reports/world-malaria-report-2021-regional-briefing-kit-eng.pdf\">Brefing kit for Regional Data & Trends</a></p>","reportYear":2021,"about":"<p>The 2021 edition of the <em>World malaria report</em> takes a historical look at key milestones that helped shape the global response to the disease over the last 2 decades – a period of unprecedented success in malaria control. The report features a detailed analysis on progress towards the 2020 milestones of WHO’s <a href=\"https://www.who.int/publications-detail-redirect/9789241564991\">global malaria strategy</a> and a special section on malaria and the COVID-19 pandemic. As in past years, the report provides an up-to-date assessment of the burden of malaria at global, regional and country levels. It tracks investments in malaria programmes and research as well as progress across all intervention areas. This latest report draws on data from 87 countries and territories with ongoing malaria transmission.</p>","supportemail":"gmpfeedback@who.int","emailsubject":"World Malaria Report Feedback","disclaimer":"<p>This work and content available through this Application is available under the Creative Commons Attribution-NonCommercialShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <a href='https://creativecommons.org/licenses/by-nc-sa/3.0/igo'> https://creativecommons.org/licenses/by-nc-sa/3.0/igo </a>). Under the terms of this licence, you may copy, redistribute and adapt the work made available through this Application for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<a href='http://www.wipo.int/amc/en/mediation/rules'>http://www.wipo.int/amc/en/mediation/rules </a>).</p><p>Suggested citation. World Malaria Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.</p><p>Third-party materials. If you wish to reuse material from this Application that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.</p><p>General disclaimers. The designations employed and the presentation of the material made available through this Application do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this Application. However, the material made available through this Application is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material contained in this Application lies with the user. In no event shall WHO be liable for damages arising from its use.</p><p>Map production: WHO Global Malaria Programme and WHO Public Health Information and Geographic Systems.</p>","mapdisclaimer":"<p>The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.</p><p>Data Source: World Health Organization</p><p>Map Production: Public Health Information and Geographic Information Systems (GIS) World Health Organization</p><p>World Health Organization<br/>© WHO 2016. All rights reserved</p>","abbreviations":{"ACT":"artemisinin-based combination therapy","AIDS":"acquired immunodeficiency syndrome","AL":"artemether-lumefantrine","AM":"artemether","ANC":"antenatal care","AQ":"amodiaquine","ART":"artemisinin","AS":"artesunate","AS-SP":"artesunate-sulfadoxine-pyrimethamine","AS-AQ":"artesunate-amodiaquine","AS-MQ":"artesunate-mefloquine","AS-PY":"artesunate-pyronaridine","AT":"atovaquone","CHW":"community health worker","CI":"confidence interval","CL":"clindamycline","CQ":"chloroquine","D":"doxycycline","DHA":"dihydroartemisinin","DHIS2":"District Health Information Software2","DHS":"demographic and health survey","E-2020":"eliminating countries for 2020","Global Forum":"Global Forum of Malaria-Eliminating Countries","Global Fund":"Global Fund to Fight AIDS, Tuberculosis and Malaria","GMP":"Global Malaria Programme","GMS":"Greater Mekong subregion","GPW13":"WHO’s 13th General Programme of Work","GTS":"Global technical strategy for malaria 2016–2030","Hb":"haemoglobin","HBHI":"High burden to high impact","HIV":"human  immunodeficiency virus","HMIS":"health management information system","HRP2":"histidine-rich  protein 2","iCCM":"integrated community case management","iDES":"integrated drug efficacy surveillance","IPT":"intermittent preventive treatment","IPTi":"intermittent preventive treatment in infants","IPTp":"intermittent preventive treatment in pregnancy","IQR":"interquartile range","IRS":"indoor residual spraying","ITN":"insecticide-treated mosquito net","LBW":"low birthweight","LLIN":"long-lasting  insecticidal net","MEOC":"Malaria Elimination Oversight Committee","MIS":"malaria indicator survey","MPAC":"Malaria Policy Advisory Committee","MQ":"mefloquine","NMP":"national malaria programme","NQ":"naphroquine","OECD":"Organisation for Economic Co-operation and Development","P.":"Plasmodium","PBO":"piperonyl butoxide","PG":"proguanil","PPQ":"piperaquine","PQ":"primaquine","PYR":"pyronaridine","QN":"quinine","RAcE":"Rapid Access Expansion Programme","R&D":"research and development","RBM":"RBM Partnership to End Malaria","RDT":"rapid diagnostic test","SDG":"Sustainable Development Goal","SMC":"seasonal malaria chemoprevention","SP":"sulfadoxine-pyrimethamine","T":"tetracycline","TES":"therapeutic efficacy study","UNICEF":"United Nations Children’s Fund","United Kingdom":"United Kingdom of Great Britain and Northern Ireland","USA":"United States of America","WHO":"World Health Organization"}}